NCT03639649已完成不适用
STHLM3 - Prostate Cancer Diagnostic Trial
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 58,818
- 试验地点
- 2
- 主要终点
- Number of biopsies
研究概览
简要总结
STHLM3 is a paired diagnostic trial aiming to assess whether a panel of biomarkers for prostate cancer can substantially reduce the proportion of men referred to biopsy whilst maintaining sensitivity for aggressive prostate cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 69 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Age 50-69
- •Residential address in Stockholm County
排除标准
- •Previous Prostate Cancer Diagnosis
- •Not able to comprehend inform consent material
研究组 & 干预措施
STHLM3
Experimental
干预措施: STHLM3 (Diagnostic Test)
PSA
Active Comparator
干预措施: STHLM3 (Diagnostic Test)
结局指标
主要结局
Number of biopsies
时间窗: Recorded directly after biopsy
次要结局
- Number of Gleason Score ≥ 7(Recorded directly after biopsy)
- Number of Gleason Score 6(Recorded directly after biopsy)
- Number of benign(Recorded directly after biopsy)
研究者
Henrik Grönberg
Professor
Karolinska Institutet
研究点 (2)
Loading locations...
相似试验
已完成
不适用
STHLM3 - Prostate cancer diagnostic trialMalignant neoplasm of prostateProstate cancerCancerISRCTN84445406Karolinska Institutet (Sweden)140,000
进行中（未招募）
不适用
Prostate Cancer Detection Using the Stockholm3 Test and MR/Fusion BiopsiesProstate CancerNCT03377881Karolinska Institutet12,750
已完成
不适用
STHLM3-MR: Comparing Standard With Targeted Prostate BiopsiesProstate CancerNCT02788825Karolinska Institutet687
已完成
3 期
Study of Immunotherapy to Treat Advanced Prostate CancerProstate CancerNCT00861614Bristol-Myers Squibb988
已完成
不适用
Active Surveillance for Low-risk Prostate Cancer - Evaluation of the Efficacy of Minimally Invasive Active SurveillanceProstate CancerNCT03956108Karolinska Institutet280